Our purpose

To manufacture biotech drugs faster and more efficiently so that everyone, everywhere, can get them 

Exothera is your trusted CDMO partner who can help to rapidly and efficiently complete the process development and manufacture of just the right quantity of therapeutic

Our philosophy

Taking a viral vector or RNA-based therapy from pre-clinical development to the first GMP batch for clinical trials can be a complex journey. One of the greatest hurdles is the limited access to both specialized process development expertise and GMP manufacturing facilities that can quickly and cost-effectively deliver the high-quality product needed for clinical studies and beyond.

Exothera stands as end-to-end CDMO partner, ready to help you navigate these challenges. We bring the expertise and flexibility to efficiently complete process development and manufacture the precise quantity of therapy required to move your clinical trials forward, secure additional funding, and accelerate your therapy’s journey to market.

OUR HIGHLIGHTS

Within 5 years, we achieved many milestones, testimony of our continuous strive for innovation in the way we offer our services.

2020

Incorporation of Exothera as a specialized viral vector CDMO

2022

Belgian FAMHP authority accreditation

Jan 2023

Lauch of the RNA business unit

Mid 2023

First viral vector GMP project

April 2024

Finalized IOQ of Ntensify RNA platform

May 2024

First RNA GMP project

Q3 2024

exoREADY viral vector platform fully operational